Catalent takes double action to boost cell and gene therapy services
The company acquires a pDNA CDMO and launches pDNA development and manufacturing services at its Rockville, Maryland facility
Catalent has bought Belgium-based plasmid DNA (pDNA) cell and gene therapy contract development and manufacturing organization (CDMO) Delphi Genetics.
Under the terms of the agreement, Catalent will also acquire Delphi’s proprietary STABY technology — an antibiotic-free selection system for plasmid and protein production in E. coli, which has been validated and licensed on a non-exclusive basis to leading pharmaceutical companies.
Upon completion, all of Delphi’s team, including R&D and genetic engineering scientists and technicians, regulatory specialists, and other associated roles will transfer to Catalent’s Cell and Gene Therapy business.
Founded in 2001 as a spin-off from the Université libre de Bruxelles (ULB), Delphi Genetics is a bioproduction CDMO with capabilities in handling the entire plasmid DNA development and cGMP manufacturing process.
Its operations are headquartered at a 17,000-sq. ft (1,600-m2) facility, adjacent to Catalent’s current cell therapy facilities.
Delphi provides ‘one-stop-shop’ capabilities that include process development, pilot production, plasmid design and production, strain screening and stability, and which span from preclinical to Phase III applications, using fully single-use technology.
The Delphi acquisition fast-tracks Catalent’s US expansion of plasmid capabilities at its Rockville facility.
Since acquiring the site in 2019, Catalent has upgraded the facility by adding dedicated single-use microbial capacity for plasmid DNA production. The site also offers process and analytical development for plasmid DNA, as well as research- and cGMP-grade plasmids to support its viral vector partners from initial development through to commercialization.
"Having integrated pDNA supply is a critical component for the fast and efficient production of viral vectors,” commented Manja Boerman, President, Catalent Cell & Gene Therapy. “By providing these capabilities in both Europe and the US ... we will help our partners improve processes and reduce timelines as they bring their life-changing therapies to patients.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance